ORPHA:398058
Squamous cell carcinoma of the penis
Also known as: Penile squamous cell carcinoma
Publications
2,231
88.5th percentile
Trials
29
Interventional, condition-specific
Researchers
1,272
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare urogenital tumor characterized by origin from squamous epithelial cells of the penis, most commonly the glans or inner surface of the prepuce. Macroscopically, the tumors can appear either papillary or flat and ulcerating. Histological subtypes include usual squamous cell carcinoma as the most common type, as well as basaloid, warty, verrucous, papillary, and mixed carcinomas. Patients may initially be asymptomatic but present with itching, bleeding, discharge, foul odor, and pain, as the disease progresses. Regional lymph node involvement is common, while distant metastases occur only late in the disease. Risk factors include HPV infection, smoking, poor hygiene, and HIV infection. circumcision is implicated as strongly protective.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018352
- UMLS:C0238348
- NCIT:C7729
Additional Mondo synonyms (13)
epidermoid carcinoma of penis · epidermoid carcinoma of the penis · epidermoid cell carcinoma of penis · epidermoid cell carcinoma of the penis · penile epidermoid carcinoma · penile epidermoid cell carcinoma · penile squamous car.(epidermoid) · penile squamous carcinoma (epidermoid) · penile squamous cell cancer · penile squamous cell carcinoma · penis squamous cell carcinoma · squamous cell carcinoma of penis · squamous cell carcinoma of the penis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
2,231 matched papers (1,262 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
29 matched on ClinicalTrials.gov (10 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
25
Drugs / clinical candidates · MONDO_0018352
- AFATINIB·phase 2
- ATEZOLIZUMAB·phase 2
- AVELUMAB·phase 2
- BECOTATUG VEDOTIN·phase 2
- CABOZANTINIB·phase 2
- CARBOPLATIN·phase 2
- CEMIPLIMAB·phase 2
- CISPLATIN·phase 2
- DACOMITINIB ANHYDROUS·phase 2
- DOCETAXEL·phase 2
- DOSTARLIMAB·phase 2
- ENFORTUMAB VEDOTIN·phase 2
- FLUOROURACIL·phase 2
- GEMCITABINE·phase 2
- IFOSFAMIDE·phase 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
2,231
2,231 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
2,231 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,262 in the last 10 years · high confidence · 88.5th percentile (publications denominator)
Phrase hits: 2,231 · MeSH hits: 0
Who's working on it?
1,272
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Spiess PE18 papers · 2026
Department of Genitourinary Oncology at Moffit Cancer Center, Tampa, FL.
Papers in Europe PMC - 02Chahoud J14 papers · 2026
Genitourinary Oncology Department, H. Lee Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, FL, 33612, USA. Jad.chahoud@moffitt.org.
Papers in Europe PMC - 03Cubilla AL11 papers · 2026
Instituto de Patología e Investigación, Universidad Nacional de Asunción, Asunción, Paraguay. Electronic address: antoniocubillaramos@gmail.com.
Papers in Europe PMC - 04Chaux A8 papers · 2026
Facultad de Medicina, Universidad del Norte, Asuncion, Paraguay.
Papers in Europe PMC - 05Li X8 papers · 2026
Department of Medical Oncology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518107, Guangdong, People's Republic of China.
Papers in Europe PMC - 06Muneer A8 papers · 2026
Department of Urology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Papers in Europe PMC - 07Pettaway CA7 papers · 2026
Department of Urology at The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: cpettawa@mdanderson.org.
Papers in Europe PMC - 08Wang Y7 papers · 2026
Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China; Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, China.
Papers in Europe PMC - 09Yao K7 papers · 2026
Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China; Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, China. Electronic address: yaokai@sysucc.org.cn.
Papers in Europe PMC - 10Briganti A6 papers · 2026
Vita-Salute San Raffaele University, Milan, Italy; Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
29
interventional trials for this specific condition
29 interventional trials matched this specific condition name; 10 currently recruiting in our sample. 2,527 trials are registered for squamous cell carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
29 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 95.9th percentile).
high confidence · 95.9th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
29 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06353906·RECRUITING·Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
Not reviewed·Conditions: Urologic Neoplasms · Urogenital Neoplasms · Male Urogenital Diseases · Penile Cancer·Matched via name phrase
- NCT07110038·RECRUITING·DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
Not reviewed·Conditions: Penile Squamous Cell Carcinoma (PSCC)·Matched via name phrase
- NCT07054307·RECRUITING·MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma
Not reviewed·Conditions: Penile Cancer·Matched via name phrase
- NCT06104618·RECRUITING·Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
Not reviewed·Conditions: Metastatic Penile Squamous Cell Carcinoma · Stage III Penile Cancer AJCC v8 · Stage IV Penile Cancer AJCC v8 · Unresectable Penile Squamous Cell Carcinoma·Matched via name phrase
- NCT06161532·RECRUITING·Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Not reviewed·Conditions: Small Cell Carcinoma of the Bladder · Small Cell Carcinoma of the Urinary Tract · Squamous Cell Carcinoma of the Bladder · Squamous Cell Carcinoma of the Urinary Tract·Matched via name phrase
- NCT05639972·RECRUITING·E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Not reviewed·Conditions: HPV-Associated Cervical Carcinoma · HPV-Related Carcinoma · HPV-Related Malignancy · HPV Positive Oropharyngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT07217171·RECRUITING·A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Not reviewed·Conditions: Bladder Cancer · Squamous Cell Carcinoma of the Lung · Esophageal Squamous Cell Carcinoma · Tongue Squamous Cell Carcinoma·Matched via name phrase
- NCT06505551·NOT YET RECRUITING·Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
Not reviewed·Conditions: HPV-Related Squamous Cell Carcinoma · HPV-Related Cervical Squamous Cell Carcinoma · HPV-Related Vulvar Squamous Cell Carcinoma · HPV-Related Penile Squamous Cell Carcinoma·Matched via name phrase
- NCT05686226·RECRUITING·E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Not reviewed·Conditions: Cervical Cancer · Throat Cancer · Oropharynx Cancer · Anal Cancer·Matched via name phrase
- NCT02305654·RECRUITING·International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Not reviewed·Conditions: Squamous Cell Carcinoma of the Penis, Usual Type·Matched via name phrase
Broader category: squamous cell carcinoma
2,527
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06662058·RECRUITING·Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Not reviewed·Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Cutaneous Squamous Cell Carcinoma of the Head and Neck · Head and Neck Carcinoma of Unknown Primary · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06540443·RECRUITING·Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Lymph Node Metastasis·Matched via name phrase
- NCT06599775·NOT YET RECRUITING·Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Not reviewed·Conditions: Resectable Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT07173270·NOT YET RECRUITING·Improved Oral Health in Head and Neck Cancer Survivors
Not reviewed·Conditions: Head and Neck Cancer Squamous Cell Carcinoma · Head and Neck Cancer·Matched via name phrase
- NCT07487896·RECRUITING·A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Not reviewed·Conditions: Advanced Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06659146·RECRUITING·Thermotherapy in Addition to SOC Palliative Radiotherapy
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Cutaneous Squamous Cell Carcinoma · Breast Cancer Recurrent·Matched via name phrase
- NCT07726199·RECRUITING·Study Comparing Different Neck Treatment Approaches in Patients With Oral Cancer Without Visible Neck Spread
Not reviewed·Conditions: Oral Squamous Cell Carcinoma (OSCC)·Matched via name phrase
- NCT06589609·RECRUITING·Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Not reviewed·Conditions: Oropharyngeal Squamous Cell Carcinoma (SCC)·Matched via name phrase
- NCT06915454·RECRUITING·High-Resolution PET-CT Imaging for Surgical Margin Visualization
Not reviewed·Conditions: Cancer · Solid Malignant Tumors · SCC - Squamous Cell Carcinoma · HNSCC·Matched via name phrase
- NCT06693323·RECRUITING·Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
Not reviewed·Conditions: HNSCC · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07629817·NOT YET RECRUITING·Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06648096·RECRUITING·Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Not reviewed·Conditions: Fanconi Anemia · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07392580·RECRUITING·Intralesional Chemotherapy (IC): Cisplatin + Epinephrine
Not reviewed·Conditions: Laryngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT05747625·RECRUITING·(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Metastatic Head and Neck Squamous Cell Carcinoma · Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck·Matched via name phrase
- NCT06492460·RECRUITING·2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
Not reviewed·Conditions: Squamous Cell Carcinoma of Head and Neck·Matched via name phrase
Observational and natural-history studies
4 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06565585·ENROLLING BY INVITATION·Prediction of Local Recurrence and Its Impact on Long-term Outcomes After Low-risk Glans-sparing Surgery for Penile Squamous Cell Carcinoma
Not reviewed·Conditions: Penile Cancer, Recurrent·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 9 · after dedupe 9 · already on CT.gov 1 · kept 0 · parent 0 · uncertain 8 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (8)
- ctis·2024-512827-36-00·Authorised, ongoing·MEGACEP_Prospective Phase II Study Evaluating a Multimodal Care of Inguinal Node Metastasis in Squamous Cell Carcinoma of the Penis by Bilateral Lymphadenectomy and Chemotherapy TIP
skipped — LLM skipped (--skip-llm)
- ctis·2023-510320-71-00·Cancelled·PEVOsq: Phase II basket trial evaluating the efficacy of a combination of pembrolizumab and vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- ctis·2025-521644-37-00·Authorised, ongoing·DEPECA-1 – DEfeating PEnile CAncer 1 – A Phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for advanced and metastatic penile carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN95561634·No longer recruiting·A trial for men with advanced penile cancer to see if immunotherapy is an effective treatment either given on its own or at the same time as chemotherapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN78108737·No longer recruiting·A phase II trial of docetaxel, cisplatin and 5-fluorouracil (5-FU) chemotherapy in locally advanced and metastatic carcinoma of the penis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN44453201·No longer recruiting·Will HIV-positive individuals who have drug resistance and have suppressed amount of virus in the blood on protease inhibitor regimen still remain suppressed if switched to a regimen containing bictegravir, emtricitabine and tenofovir alafenamide?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN51789191·No longer recruiting·Therapeutic HPV vaccine trial +/- anti-CD40 in HPV-driven squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17627211·No longer recruiting·The PACE Study
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Squamous cell carcinoma of the penis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Squamous cell carcinoma of the penis" OR "Squamous cell carcinoma of penis" OR "Penile squamous cell carcinoma" OR "epidermoid carcinoma of penis" OR "epidermoid carcinoma of the penis" OR "epidermoid cell carcinoma of penis" OR "epidermoid cell carcinoma of the penis" OR "penile epidermoid carcinoma" OR "penile epidermoid cell carcinoma" OR "penile squamous car.(epidermoid)" OR "penile squamous carcinoma (epidermoid)" OR "penile squamous cell cancer" OR "penis squamous cell carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Squamous cell carcinoma of the penis" OR "Squamous cell carcinoma of penis" OR "Penile squamous cell carcinoma" OR "epidermoid carcinoma of penis" OR "epidermoid carcinoma of the penis" OR "epidermoid cell carcinoma of penis" OR "epidermoid cell carcinoma of the penis" OR "penile epidermoid carcinoma" OR "penile epidermoid cell carcinoma" OR "penile squamous car.(epidermoid)" OR "penile squamous carcinoma (epidermoid)" OR "penile squamous cell cancer" OR "penis squamous cell carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 29 interventional · 4 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"squamous cell carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T15:16:47.982Z
